- 04/02/2018
- EISAI SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FDA FOR FYCOMPA® AS TREATMENT FOR PEDIATRIC PATIENTS WITH EPILEPSY
- 03/23/2018
- Anticancer Agent LENVIMA® Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC
- 03/12/2018
- Innovation, Joint efforts, Defense -- Shinsei Electronics management visited Eisai (China) headquarter
- 01/11/2018
- EISAI COMPLETES CONSTRUCTION OF ORAL SOLID DOSE PRODUCTION FACILITY AT NEW SUZHOU PLANT IN CHINA
- 12/27/2017
- ANTICANCER AGENT LENVATINIB DESIGNATED FOR PRIORITY REVIEW AND APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION FOR HEPATOCELLULAR CARCINOMA
- 12/13/2017
- ARICEPT® APPROVED FOR ADDITIONAL INDICATION OF SEVERE ALZHEIMER’S DISEASE IN CHINA
- 10/31/2017
- NEW DRUG APPLICATION OF ANTICANCER AGENT LENVATINIB FOR HEPATOCELLULAR CARCINOMA ACCEPTED IN CHINA
- 09/29/2017
- EISAI PRESENTS RESULTS OF PHASE III TRIAL OF LENVIMA® (LENVATINIB) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA IN ORAL SESSION AT 20TH CSCO ANNUAL MEETING
- 09/19/2017
- EISAI PRESENTS RESULTS OF PHASE III CLINICAL STUDY OF LENVIMA® (LENVATINIB) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA AT 11TH ILCA ANNUAL CONFERENCE
- 09/15/2017
- Eisai China Joins Hands with Partners to Kick off “Alzheimer’s Care” for the Well-being of Chinese Families
